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Abstract  54 
 55 
Routine full characterization of Mycobacterium tuberculosis (TB) is culture-56 
based, taking many weeks. Whole-genome sequencing (WGS) can generate 57 
antibiotic susceptibility profiles to inform treatment, augmented with strain 58 
information for global surveillance; such data could be transformative if 59 
provided at or near point of care. 60 
 61 
We demonstrate a low-cost DNA extraction method for TB WGS direct from 62 
patient samples. We initially evaluated the method using the Illumina MiSeq 63 
sequencer (40 smear-positive respiratory samples, obtained after routine clinical 64 
testing, and 27 matched liquid cultures). M. tuberculosis was identified in all 39 65 
samples from which DNA was successfully extracted. Sufficient data for 66 
antibiotic susceptibility prediction was obtained from 24 (62%) samples; all 67 
results were concordant with reference laboratory phenotypes. Phylogenetic 68 
placement was concordant between direct and cultured samples. Using an 69 
Illumina MiSeq/MiniSeq the workflow from patient sample to results can be 70 
completed in 44/16 hours at a reagent cost of £96/£198 per sample.  71 
 72 
We then employed a non-specific PCR-based library preparation method for 73 
sequencing on an Oxford Nanopore Technologies MinION sequencer. We applied 74 
 4
this to cultured Mycobacterium bovis BCG strain (BCG), and to combined culture-75 
negative sputum DNA and BCG DNA. For flowcell version R9.4, the estimated 76 
turnaround time from patient to identification of BCG, detection of pyrazinamide 77 
resistance, and phylogenetic placement was 7.5 hours, with full susceptibility 78 
results 5 hours later. Antibiotic susceptibility predictions were fully concordant. 79 
A critical advantage of the MinION is the ability to continue sequencing until 80 
sufficient coverage is obtained, providing a potential solution to the problem of 81 
variable amounts of M. tuberculosis in direct samples. 82 
 83 
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 100 
 101 
Introduction 102 
 103 
The long-standing gold standard for Mycobacterium tuberculosis drug 104 
susceptibility testing (DST) is the phenotypic culture-based approach, which is 105 
time-consuming and laborious. First-line tuberculosis (TB) treatment includes 106 
four drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) but with the 107 
spread of multi-drug resistant strains, there is a growing need for data on 108 
second-line drugs, including the fluoroquinolones, and aminoglycosides. 109 
 110 
Due to long turnaround times for phenotypic testing (up to two months), these 111 
are often preceded by WHO-endorsed molecular methods such as the GenoType 112 
MTBDRplus and MTBDRsl assays (Hain Lifescience GmbH, Germany), and Xpert 113 
MTB/RIF (Cepheid, USA). These potentially culture-free, PCR-based tests rapidly 114 
identify species and detect the most common drug resistance conferring 115 
mutations. However, this technology is limited by the number of mutations that 116 
can be probed. This limitation is of concern, given the many low frequency drug 117 
resistance conferring mutations in M. tuberculosis, particularly for second-line 118 
drugs (1). Consistent with this concern, the proportion of phenotypically 119 
resistant samples which are detectable by MTBDRplus range from 21-25% for 120 
the second-line drugs capreomycin and kanamycin (2) to 98.4% and 91.4% for 121 
the critical first-line drugs rifampicin and isoniazid (3). A potential solution is to 122 
sequence amplicons targeting a wider range of resistance conferring genes, as 123 
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previously demonstrated (4).  124 
 125 
The potential of whole genome sequencing (WGS) as a diagnostic assay has been 126 
repeatedly identified (5-7). Recent studies based on WGS of mycobacteria have 127 
evaluated WGS-based susceptibility predictions (1, 8-10), species identification, 128 
and elucidation of epidemiology (11-16). This has culminated in the first 129 
successful application of WGS as a clinical diagnostic for mycobacteria from early 130 
positive liquid cultures (16). Moreover, WGS was performed at a cost 131 
comparable with existing phenotypic assays and offered faster turnaround times.  132 
 133 
Generating WGS information directly from patient samples, and avoiding the 134 
need for culture, would be transformative. However, direct samples contain 135 
highly variable amounts of mycobacterial cells mixed with other bacterial and 136 
human cells; the latter accounting for up to 99.9% of DNA present. Furthermore, 137 
mycobacterial cells may aggregate due to the high mucus content of some 138 
samples; meaning sample volume and Acid Fast Bacillus (AFB) count may not 139 
represent the total quantity of mycobacteria available. Direct samples therefore 140 
require pre-processing to homogenize and enrich for mycobacteria by depleting 141 
other cells/DNA. The challenges of direct sample processing were illustrated by 142 
two studies assessing the feasibility of WGS directly from clinical samples (17-143 
18). By sequencing eight smear-positive sputum samples subjected to 144 
differential lysis followed by DNA extraction with a commercial kit, Doughty and 145 
colleagues were able to achieve only 0.002-0.7X depth of coverage for M. 146 
tuberculosis with 20.3-99.3% of sequences mapping to the human genome. 7/8 147 
samples could be assigned to M. tuberculosis complex, but none had sufficient 148 
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data for drug susceptibility prediction. In a second study, Brown and colleagues 149 
applied a SureSelect target enrichment method (Agilent, USA) to capture M. 150 
tuberculosis DNA prior to WGS. 20/24 smear-positive samples achieved 90% 151 
genome coverage with ≥20x depth; sufficient for prediction of species and 152 
antibiotic susceptibility. However, the protocol was slow (2-3 days) and may be 153 
prohibitively expensive for use in low-income settings. 154 
 155 
In this study we test a simple low-cost DNA extraction method using Illumina 156 
MiSeq WGS on 40 smear-positive, primary respiratory samples from M. 157 
tuberculosis infected patients. We evaluate the protocol in terms of DNA 158 
obtained, species assignment of the sequenced reads, and our ability to obtain 159 
key clinical data (detection of M. tuberculosis and antibiotic susceptibility 160 
prediction) along with epidemiological information (placement on phylogenetic 161 
tree). These data would enable a single test to deliver the core information for 162 
both patient and public health in <48 hours using Illumina-based WGS. We also 163 
develop an approach for WGS using the highly portable, random-access, Oxford 164 
Nanopore Technologies (ONT) MinION, reducing potential turnaround time to 165 
below 12 hours.  166 
 167 
 168 
 169 
 170 
 171 
 172 
 173 
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 174 
 175 
Results 176 
 177 
DNA extraction protocol and evaluation of Illumina sequencing output 178 
 179 
DNA was extracted from 40 ZN-positive direct respiratory samples, of which 38 180 
were culture-confirmed M. tuberculosis (“culture-positive”) and 2 were culture-181 
negative. DNA was also extracted from 28 available corresponding mycobacteria 182 
growth indicator tube (MGIT) cultures. All direct samples were the remainder of 183 
specimens available after processing by the routine laboratory, and therefore 184 
had variable volume (median 1.5 ml, IQR 0.5-3.1, range 0.25-15) and age 185 
(median 30 days from collection to processing, IQR 15-45, range 0-67). Most 186 
direct samples (78%; 31/40) could therefore be considered suboptimal on the 187 
basis of either low volume (≤1ml) or long storage time (≥30 days) or both. 188 
 189 
After DNA extraction, 33/40 (83%) direct samples and all 28 MGIT cultures 190 
yielded ≥0.2 ng/µl DNA, the amount recommended for MiSeq Illumina library 191 
preparation (Figure 1). 192 
 193 
There was no evidence that DNA yield was affected (either in multivariable or 194 
univariable models) by (1) sample type (sputum or bronchoalveolar lavage) 195 
(p=0.94; univariable linear regression), (2) AFB scorings (from +1 to +3) 196 
(p=0.56), (3) storage time prior to DNA extraction (days from collection) 197 
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(p=0.51) and (4) sample volume (p=0.28). Although DNA concentration was 198 
measured and recorded after extraction, further data on DNA quality (e.g. DNA 199 
Integrity Number (DIN) provided by TapeStation (Agilent, USA)) were not 200 
routinely recorded.  201 
 202 
In total 39/40 direct samples with detectable DNA (37 culture-positive, 2 203 
culture-negative) and 27/28 MGIT cultures were sequenced on an Illumina 204 
MiSeq. One MGIT culture was not sequenced because the corresponding direct 205 
sample failed to yield measurable DNA. We used a lower than recommended 206 
DNA concentration threshold for MiSeq library preparation (>0.05 ng/µl rather 207 
than >0.2 ng/µl) on the basis of previous experience of sequencing mycobacterial 208 
cultures with suboptimal amounts of DNA (19). 6/40 (15%) samples yielded 209 
DNA below the 0.2 ng/µl threshold. All sequenced direct samples produced ≥1.5 210 
million reads (median 3.6 million, IQR 2.9-5.0, range 1.5-12), as did all MGIT 211 
cultures (median 3.1 million, IQR 2.8-3.3, range 2.0-4.1).  212 
 213 
Contamination levels of direct and MGIT samples 214 
 215 
We assigned reads to categories M. tuberculosis, human, naso-pharyngeal flora 216 
(NPF) and “other” by mapping (see Methods). 77% (30/39) of direct samples 217 
contained <10% human reads. However, only 46% (18/39) contained <10% NPF 218 
and other bacterial reads, and 26% (10/39) contained >40% of reads from non-219 
mycobacterial, non-NPF, bacteria (Figure 2a). By comparison, MGIT culture 220 
samples showed much less contamination, as expected (Figure 2b).  221 
 222 
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Recovery of M. tuberculosis genome 223 
 224 
Figure 3a shows the distribution of the M. tuberculosis reference genome depth 225 
of coverage across direct samples. 21/39  samples have more than 12x depth and 226 
recover more than 90% of the genome, and 14/39 samples have <3x depth and 227 
recover less than 12% of the genome. The vertical dotted line delineates our 228 
threshold of 3x coverage, below which resistance predictions were not made. 229 
Figure 3b shows the amount of contamination (reads not mapping to M. 230 
tuberculosis) per sample. Ten samples had <15% contaminant reads, although 231 
contamination levels increased as high as 75% before the proportion of the M. 232 
tuberculosis genome recovered started to drop. Low numbers of M. tuberculosis 233 
reads could also reflect poor DNA quality from samples stored for long periods, 234 
as most of the samples with <80% reference genome coverage (12/17, 71%) 235 
were more than 3 weeks old before extraction. 236 
 237 
Concordance of results from direct and MGIT samples  238 
 239 
We took a set of 68,695 high quality single-nucleotide polymorphisms (SNPs) 240 
obtained from analysis of 3480 samples (1), and genotyped all samples at these 241 
positions (see Methods). This allowed us to calculate a genetic distance between 242 
the 17 paired MGIT and direct samples (after excluding 10 pairs where the direct 243 
sample had <5x coverage, to avoid systematic undercalling in direct samples). 244 
The median (and modal) SNP difference was 1 (Figure 4a), with one outlier pair 245 
of samples that differed by 1106 SNPS, discussed below, and all other differences 246 
≤22 SNPs.  247 
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 248 
We placed 17 paired direct and MGIT samples on the phylogeny from (1) (see 249 
Methods). Our samples were distributed across global diversity (Figure 4b; tree 250 
thinned to aid visibility). For the pair with 1106 SNP differences, the direct 251 
sample was isolated on the tree, but the MGIT sample was placed very closely to 252 
3 other pairs (0 SNP difference to one MGIT sample, and 5 SNP differences to the 253 
others). Although this might result from different strains being present within 254 
the host, a within-laboratory labelling error or cross-contamination is also 255 
possible.  256 
 257 
No evidence of higher diversity in direct samples 258 
 259 
Comparing direct/MGIT pairs where both samples had at least 20x mean depth 260 
of coverage on the M. tuberculosis reference, the median number of high 261 
confidence (see Methods) heterozygous sites was 25 in both direct and MGIT 262 
samples. There was no clear trend of greater genome-wide diversity in direct 263 
samples (Supplementary Figure 1).  264 
 265 
Detection of M. tuberculosis in culture positive/negative samples 266 
 267 
All sequenced culture-positive (37/39) direct M. tuberculosis samples were 268 
successfully identified by Mykrobe predictor to complex level (37/37) and 95% 269 
to species level (35/37), including 13/37 (35%) where the mean depth of 270 
coverage was <3x. All MGIT cultures were identified as M. tuberculosis. We were 271 
also able to identify M. tuberculosis in 2/2 direct samples with low AFB scores 272 
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(+1) and no growth in MGIT culture; these may represent dead bacilli from a 273 
patient undergoing treatment.  274 
 275 
Antibiotic resistance prediction 276 
 277 
In total 168 predictions for first-line (n=96) and second-line (n=72) antibiotic 278 
susceptibility were made for the 24/37 (65%) direct samples which had at least 279 
3x depth (Supplementary Tables 1,2). For the 13/37 (35%) samples that had <3x 280 
depth, no resistance predictions were made. This included 1/2 culture-negative 281 
samples.  282 
 283 
92/96 (96%) predictions for the first-line antibiotics were concordant with 284 
reference laboratory DST. The four mismatches (three pyrazinamide mixed 285 
genotypes with both R and S alleles present, and one rifampicin resistant 286 
genotype with sensitive phenotype) were found across three samples, all from 287 
the same patient (patient 2 in Supplementary Table 2) who had a variable 288 
phenotype for rifampicin and pyrazinamide. The resistant genotype for 289 
rifampicin was consistent across all three samples from this patient 290 
(rpoB_I491F). There is evidence that this mutation causes resistance, but that the 291 
phenotype is often reported as sensitive (27,28,1). The mixed genotype for 292 
pyrazinamide was again consistent with presence of both R and S alleles on 293 
pncA_V7L across all three samples, whereas the phenotype varied. This mutation 294 
is also known to confer resistance in samples reported as phenotypically 295 
sensitive (1). Further, 1/3 samples from this patient (sample 602112, 296 
Supplementary Table 2) contained two additional mutations conferring 297 
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resistance to isoniazid and pyrazinamide, katG_S315T and pncA_T135P 298 
respectively, which were not detected in the previous or following sample. This 299 
variation between genotypes from same-patient samples taken over time may 300 
represent ongoing evolution, changing population size, and within-patient 301 
diversity of M. tuberculosis as previously demonstrated by Eldholm et al (29). In 302 
addition to the above, WGS provided 72 predictions for second-line antibiotics 303 
where DST was not attempted.  304 
 305 
The 13/37 samples that yielded insufficient WGS data for resistance prediction 306 
had a higher proportion of other bacterial DNA (Figure 3b; median 96%, IQR 38-307 
70%, vs median 12%, IQR 0-67%, in those where resistance prediction was 308 
possible, rank-sum p=0.01). 309 
 310 
Sub-24 hour turnaround time with Illumina MiniSeq 311 
 312 
Illumina MiniSeq sequencing for three samples (single run; 1 pure BCG, 2 313 
negative sputum DNA spiked with BCG DNA) was completed in 6 hours 40 314 
minutes. BCG reference genome coverage was 31-33x in spiked samples, and 84x 315 
in pure BCG (Table 1). In all cases the species/strain was correctly identified as 316 
M. bovis strain BCG, and pyrazinamide resistance was correctly identified due to 317 
mutation H57D in pncA. 318 
 319 
Modified method for ONT MinION  320 
 321 
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A new PCR-based rapid 1D MinION protocol was tested using extracted BCG 322 
DNA, ZN-negative sputum DNA spiked with BCG DNA, and R9 flowcells (see 323 
Methods). Analysis of genome-wide coverage distribution confirmed that use of 324 
PCR had not led to significant coverage bias (Supplementary Figure 2), and that 325 
>95% of the reference genome attained coverage >5x for all samples. In all cases 326 
Mykrobe correctly identified the species/strain as M. bovis strain BCG (Table 2). 327 
Amplification with Phusion High-Fidelity master mix resulted in the highest yield 328 
(760Mb, with 68x coverage of BCG). All MinION experiments resulted in correct 329 
identification of the H57D mutation in pncA that confers pyrazinamide resistance 330 
in BCG, but in the 5% spike this call was filtered out as it only had kmer coverage 331 
of 1x on the resistant allele, and did not achieve the required confidence 332 
threshold. In all cases, no false resistance calls were made, but deep coverage 333 
was needed to be able to genotype all 175 mutations in the catalogue 334 
(Supplementary Table 3). Although the pure BCG/R9 and 15% BCG/Phusion/R9 335 
runs missed only 3/175 and 1/175 mutations respectively, (Table 2), only the 336 
R9.4 sequencing run (below) allowed all mutations to be typed. 337 
 338 
In all 5 samples sequenced on R9 flowcells, data yield was highest at the start of 339 
the run, with consistent yield profiles. For the Phusion/15% run we obtained 340 
over 65% of the data in 8 hours, and 80% in 10 hours (Supplementary Figure 3). 341 
Despite the high sequencing error rate (Supplementary Figure 4), high accuracy 342 
genotyping of known SNPs/indels was achievable as described above. 343 
 344 
Using two independent methods (see Methods) we measured a strong bias in the 345 
distribution of SNP errors in the consensus of the MinION data. Both methods 346 
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agreed the bias was systematic, consistent with a strong A->G error bias within a 347 
1D read (Supplementary Tables 4,5), but differed in their determination of the 348 
strength of the bias (28% versus 50% A->G respectively). A filter to ensure SNP 349 
calls have support from reads mapping to both strands could remove such 350 
errors.  351 
 352 
12.5 hour turnaround time with ONT R9.4 MinION 353 
 354 
We sequenced a single sample (15% BCG spiked ZN-negative sputum) on the 355 
latest R9.4 MinION flowcell (see Methods). Yield was 1.3Gb in 48 hours. We were 356 
able to detect M. tuberculosis complex, identify the strain as BCG, detect the 357 
correct pyrazinamide resistance mutation and correctly place the sample on the 358 
phylogenetic tree after 1 hour of sequencing. After 3 hours 170/175 mutations 359 
were genotyped confidently, after 4 hours we had definitive results for all drugs 360 
except streptomycin, and after 6 hours we had definitive results for streptomycin 361 
and could stop sequencing. One pyrazinamide mutation remained un-genotyped, 362 
but since we already had a confident resistance call for pyrazinamide, there 363 
would be no need to continue. Sufficient coverage on the final mutation was 364 
obtained after a further 3 hours (9 hours total sequencing; Table 3). 365 
Incorporating 6.5 hours for decontamination, DNA extraction and sample 366 
preparation (Figure 5), this would give a turnaround time of 7.5 hours for 367 
identifying species, phylogenetic placement and initial susceptibility predictions, 368 
and 12.5 hours for complete results. 369 
 370 
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We took our phylogenetic placement of the MiniSeq BCG data as truth, 4 SNPs 371 
distant from a BCG sample on the predefined tree. After 1 hour of sequencing 372 
with R9.4, we were able to confidently genotype 22694 of the 68695 SNPs, 373 
placing the sample at the correct leaf of the tree, at an estimated distance of 3 374 
SNPs. Thus, our genotyping on 1D nanopore reads had at most 7 errors (=3+4) 375 
out of 22694 SNPs - an error rate below 0.03%.   376 
Finally, based on the performance of the 1.3Gb R9.4 sequencing run, we estimate 377 
(see Methods) that full susceptibility prediction would fail to be generated for 378 
17/39 of the sputum samples sequenced here (MiSeq) with <8% M. tuberculosis. 379 
However, for the 11/39 samples with >84% M. tuberculosis, species-380 
identification and initial susceptibility predictions would be obtained within 20 381 
minutes of sequencing, and full results within 93 minutes (Supplementary figure 382 
8 and Supplementary Table 6).    383 
 384 
Costing  385 
Reagent costs (sample decontamination, extraction, sequencing library 386 
preparation, and sequencing) per sample were £96 (MiSeq, 12 samples/run), 387 
£198 (MiniSeq, 3 samples/run), £515 (R9 MinION, 1 sample/run), £101-172 388 
(R9.4 MinION, between 3 and 5 samples/run, approximate cost as multiplexing 389 
kit not yet available). See Supplementary Table 7 for details. 390 
 391 
 392 
Discussion 393 
 394 
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Anticipating a growing knowledge-base of the molecular determinants of 395 
antibiotic resistance (1), we have developed a method of extracting and purifying 396 
mycobacterial DNA from primary clinical samples and producing accurate 397 
sequence data in a clinically useful timeframe. We have demonstrated: first, that 398 
direct WGS of sputum is possible, and gives genotypic DST predictions which are 399 
concordant with phenotype and concordant phylogenetic placement with 400 
culture-based sequencing. Second: using an Illumina MiSeq sequencer, we can 401 
obtain results within 48 hours for <£100 consumable costs per sample. Using an 402 
Illumina MiniSeq can deliver a same-day test (16 hours) for an estimated 403 
consumable cost of £198 per sample. Although the costs presented here only 404 
represent reagents, they are still likely to be below that of traditional 405 
phenotyping (£518 to provide first-/second- line DST and MIRU-VNTR in a 406 
bottom-up costing including, for example, consumables, staff time and overheads 407 
(16); versus £495 for MiSeq under the same costing model). The MiSeq 408 
consumables cost is also well below that of the SureSelect procedure (£203 per 409 
sample) (18).  410 
 411 
The World Health Organisation (WHO) has called for affordable and accessible 412 
point-of-care TB diagnostics, including for DST. Current molecular assays 413 
provide partial information on some drugs, but do not easily scale to incorporate 414 
a growing list of recognized resistance mutations. Furthermore, additional 415 
assays are currently needed where surveillance or outbreak detection are 416 
indicated, at additional cost. A single assay providing diagnostic information, and 417 
data for surveillance and outbreak detection is therefore an attractive prospect.  418 
 419 
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In cities where there are large numbers of TB cases (for example upward of 420 
65,000 TB cases per years in Mumbai) centralized sequencing services taking 421 
advantage of high throughput Illumina sequencing platforms may be applicable. 422 
However, at current prices in 2017, the relatively high capital costs, and 423 
requirement for a well-equipped laboratory are an impediment to 424 
implementation across the full range of locations across the world. For a 425 
complete solution, the ability to function in varied low-tech environments is a 426 
practical necessity. The MinION can deliver this at least on a small-scale, as 427 
demonstrated in Guinea last year during the Ebola outbreak (30). We confirm 428 
here that, despite the high error rate in reads, given deep coverage, it is possible 429 
to accurately genotype resistance SNPs using the MinION method applied here. 430 
However, widespread implementation would require much larger feasibility 431 
studies, similar to those recently conducted to implement MiSeq sequencing 432 
from MGIT samples for Mycobacteria diagnosis by Public Health England.  433 
 434 
Since with Illumina technology the depth of sequencing is determined in advance 435 
(by the number of isolates run in a batch), the small amount of M. tuberculosis in 436 
a direct sample can result in test failures. In this experiment M. tuberculosis 437 
identification and susceptibility prediction failed in 2/39 and 13/37 samples 438 
respectively. MinION sequencing in theory allows sequencing to continue until 439 
sufficient coverage has been obtained, giving faster results when there is high 440 
load, and avoiding this type of failure when the load is low. The throughput 441 
obtained here with a 15% BCG-spiked sputum sample and R9.4 flowcells (1.3 442 
Gb) would allow a turnaround time of 12.5 hours (sample to complete results); 443 
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or only 7.5 hours to detection of M. tuberculosis, pyrazinamide resistance and 444 
placement on a phylogenetic tree.  445 
 446 
We have predicted that species and initial DST could be generated after 20 447 
minutes (mean) of sequencing using MinION R9.4, and final DST within 150 448 
minutes; providing the M. tuberculosis concentrations are sufficient (>=20% of 449 
total sequencing reads in this study). For these samples, it would be possible to 450 
multiplex sequencing and reduce per-sample costs.  Conversely, for samples with 451 
low M. tuberculosis concentrations nanopore sequencing would not provide 452 
sufficient data within 48 hours. Although these predictions are based on a single 453 
R9.4 sequencing run, the data demonstrate clear scope for technology-driven 454 
improvement, either through improved mycobacterial enrichment and/or non-455 
mycobacterial DNA depletion (Figure 2a), higher sequencing yield, or real-time 456 
filtering of contamination (31).  457 
 458 
Were this methodology implemented in clinical practice, we would expect a 459 
portion of direct sample would be retained for culture in all cases; this would be 460 
available for resequencing in case of insufficient sequencing depth, and would 461 
allow distinction between live and dead bacilli. Unlike our study, where we had 462 
to use sample discards after clinical processing, if implemented, increased 463 
sample volume could be used for sequencing, closer to the time the sample was 464 
taken, presumably with greater success. Both Illumina and ONT technologies 465 
would require some level of sample batching, but for both, turnaround time is 466 
likely to be much faster than traditional phenotyping and could challenge same-467 
day molecular tests such as Xpert MTB/RIF.  468 
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 469 
In conclusion, diagnostic and surveillance information direct from patient 470 
specimens can now be obtained in 16/44 hours on Illumina MiniSeq/MiSeq 471 
platforms, a considerable step forward. In addition, the ONT sequencing platform 472 
may offer the same information in as little as 7-12.5 hours. Faster and more 473 
automated sample processing, as well as cost reductions, are clearly needed for 474 
adoption in low-income settings. Achieving this would revolutionize the 475 
management of TB. 476 
 477 
 478 
 479 
 480 
Materials and Methods 481 
 482 
 483 
Sample selection and processing 484 
Direct respiratory Ziehl-Neelsen (ZN)-positive samples with acid-fast bacilli 485 
(AFB) scorings from +1 to +3 used in this study had been originally collected 486 
from patients with subsequently confirmed M. tuberculosis infections at the John 487 
Radcliffe Hospital, Oxford Universities NHS Foundation Trust, Oxford, UK (n=18), 488 
and Birmingham Heartlands Hospital NHS Foundation Trust, Birmingham, UK 489 
(n=22). 2/18 Oxford samples were culture negative specimens taken 2.5 months 490 
apart from the same patient undergoing treatment for M. tuberculosis. If 491 
available, corresponding Mycobacterial Growth Indicator Tube (MGIT) cultures 492 
 21
were collected for each direct sample (Oxford n=11, Birmingham n=17). Two ZN 493 
and culture negative direct respiratory samples were also collected from the 494 
John Radcliffe Hospital. 495 
 496 
The discarded direct samples were collected only after sufficient material had 497 
been obtained for the routine diagnostic workflow, including the requirement to 498 
ensure that enough sample volume remained if re-culture was requested. 499 
Consequently, study samples were of lower volume and quality than would be 500 
the case if the method were used routinely. While waiting for the routine 501 
laboratory results, samples were stored at +4C and later processed in batches of 502 
5-12. All ZN-positive samples were digested and decontaminated with NAC-PAC 503 
RED kit (AlphaTec, USA). Direct samples and corresponding MGIT culture 504 
aliquots (1 mL) were heat inactivated in a thermal block after sonication (20 505 
min, 35 kHz) for 30 min and 2 h at 95C, respectively. MGITs were inactivated for 506 
2 hours owing to their high bacterial load. Before DNA extraction samples were 507 
stored at +4C. 508 
 509 
DNA extraction and Illumina MiSeq sequencing 510 
Mycobacterial DNA from MGIT cultures was extracted using a previously 511 
validated ethanol precipitation method (19). DNA from ZN-positive direct 512 
samples was extracted using a modified version of this protocol. These 513 
modifications included a saline wash followed by MolYsis Basic5 kit (Molzym, 514 
Germany) treatment for the removal of human DNA, and addition of GlycoBlue 515 
co-precipitant (LifeTechnologies, USA) to the ethanol precipitation step 516 
(Supplementary Figure 5).  517 
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 518 
Libraries were prepared for the MiSeq Illumina sequencing using a modified 519 
Illumina Nextera XT protocol (19). Samples were sequenced using the MiSeq 520 
Reagent Kit v2, 2 x 150bp in batches of 9-12 per flow-cell. Median library size 521 
(Tapestation, Agilent, USA) was 627 bp (IQR 495 – 681). Median reads available 522 
per sample was 3.2 million (IQR 2.8 – 4.1 million); this would yield a median 523 
depth of approximately 213, given pure M. tuberculosis, although in this study we 524 
anticipated non-mycobacterial reads would be present. 525 
 526 
DNA extraction for ONT MinION and Illumina MiniSeq sequencing 527 
ZN/culture-negative sputum and BCG (Pasteur strain; cultivated at 37C in MGIT 528 
tubes) DNA was extracted using a modified version of that in (19). Briefly, 529 
following a saline wash, samples were re-suspended in 100 µL of molecular 530 
grade water and subjected to three rounds of bead-beating at 6 m/s for 40 531 
seconds. The beads were pelleted by centrifugation at 16,100 xg for 10 minutes 532 
and 50 µL supernatant cleaned using 1.8x volume AMPure beads (Beckman 533 
Coulter, UK). Samples were eluted in 25 µL molecular grade water, and 534 
quantified using the Qubit fluorimeter (Thermo Fisher Scientific, USA). (Steps I, 535 
III, V and VI of Miseq protocol, Supplementary Figure 5.) 536 
 537 
MiniSeq sequencing 538 
Extracted ZN-negative sputum DNA and pure BCG DNA were combined in a 539 
50:50 ratio (0.5 ng each) and libraries prepared alongside pure BCG DNA (1 ng) 540 
using a modified Illumina Nextera XT protocol (19). BCG and two BCG+sputum 541 
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DNA samples were sequenced at Illumina Cambridge Ltd. UK, using a Mid Output 542 
kit (FC-420-1004) reading 15 tiles and with 101 cycles.  543 
 544 
MinION sequencing 545 
All MinION sequencing utilized the best available sample preparation kit for our 546 
samples and flow cells (R9/R9.4 flowcells and PCR-based sample preparation, as 547 
described below). A single ZN-negative sputum extract was divided into three 548 
equal concentration aliquots (187 ng), and BCG DNA added at 5%, 10% and 15% 549 
of the total sputum DNA concentration. These 5-15% spikes represent the lower 550 
end of the spectrum seen in the MiSeq samples above (see Figure 2a). These 551 
samples, along with pure BCG DNA, were prepared following ONTs PCR-based 552 
protocol for low-input libraries (DP006_revB_14Aug2015), using modified 553 
primers supplied by ONT, a 20 ng DNA input into the PCR reaction, and LongAmp 554 
Taq 2X Master Mix (New England Biolabs, USA). PCR conditions were as follows: 555 
initial denaturation at 95°C for 3 minutes, followed by 18 cycles of 95°C for 15s, 556 
62°C for 15s, and 65°C for 2.5 minutes, and a final extension at 65°C for 5 557 
minutes. Samples were cleaned in 0.4x volume AMPure beads and the PCR 558 
product assessed using the Qubit fluorimeter and TapeStation (Agilent, UK). The 559 
final elution was into 10 µL 50 mM NaCl, 10 mM Tris.HCl pH8.0. Finally, 1 µL of 560 
PCR-Rapid Adapter (PCR-RAD; supplied by ONT) was added and samples 561 
incubated for 5 minutes at room temperature to generate pre-sequencing mix. 562 
The pre-sequencing mix was prepared for loading onto flow cells following 563 
standard ONT protocols, with a loading concentration of 50 – 100 fmol.  564 
 565 
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Using the 15% BCG spiked sputum DNA prepared above, amplification was 566 
repeated using Phusion High-Fidelity PCR Master Mix with DMSO (New England 567 
BioLabs, USA). Gradient PCR was performed to identify the optimal annealing 568 
temperature for recovery of BCG DNA (data not shown). Final PCR conditions 569 
were as follows: initial denaturation at 98°C for 30s, followed by 18 cycles of 570 
98°C for 10s, 59°C for 15s, and 72°C for 1.5 minutes, and a final extension of 72°C 571 
for 10 minutes. Following PCR, the sample was prepared for sequencing as 572 
described above. The final loading concentration was approximately 27 fmol.  573 
 574 
The above samples were sequenced using R9 spot-on generation flow cells and 575 
the 48-hour protocol for FLO-MIN105 (ONT, UK). Base calling was performed via 576 
the Metrichor EPI2ME service (ONT, UK) using the 1D RNN for SQK-RAD001 577 
v1.107 workflow.  578 
 579 
Subsequently, a new 15% BCG spiked sputum was prepared as described above 580 
using Phusion Master Mix with DMSO. Sequencing was performed using R9.4 581 
spot-on generation flow cells and the 48-hour FLO-MIN106 protocol (ONT, UK). 582 
Final loading concentration was 43 fmol. Base calling was performed after 583 
sequencing was complete using Albacore (ONT, UK), as base calling via Metrichor 584 
failed.  Subsequent tests on other samples (data not shown) showed that base-585 
calling could have been performed in real-time – during the run. 586 
 587 
Bioinformatic analysis of Illumina data 588 
To determine levels of contamination and M. tuberculosis in samples, reads were 589 
immediately mapped using bwa_mem (20) to the human reference genome 590 
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GRCh37 (hg19) and human reads counted and permanently discarded. 591 
Remaining stored reads were then mapped to the M. tuberculosis H37Rv 592 
reference strain (GenBank NC_018143.2), and any unmapped reads were then 593 
mapped to nasal, oral and mouth flora available in the NIH Human Microbiome 594 
Project database (http://www.hmpdacc.org/).  595 
 596 
Mycobacterial species and antibiotic resistance to isoniazid, rifampicin, 597 
ethambutol, pyrazinamide, streptomycin, aminoglycosides (including 598 
capreomycin, amikacin and kanamycin) and fluoroquinolones (including 599 
moxifloxacin, ofloxacin, and ciprofloxacin) was predicted using Mykrobe 600 
predictor software (21) v0.3.5, updated with a new validated catalogue of 601 
resistance conferring genetic mutations (Supplementary Table 3, from (1)). For 602 
samples where the estimated depth of kmer-coverage of M. tuberculosis reported 603 
by Mykrobe predictor fell below 3x, no resistance predictions were made. The 604 
precise command used was:,``mykrobe predict SAMPLE_ID tb -1 FASTQ –panel 605 
walker-2015 –min-depth 3”.   606 
 607 
Phylogenetic analysis of pairs 608 
Conservative SNP calls were made using Cortex (22) (independent workflow, 609 
k=31) on 3480 samples from (1). Singleton variants were discarded, and a de-610 
duplicated list of 68695 SNPs was constructed. All samples (from our study and 611 
from (1)) were genotyped at these sites using the Mykrobe predictor genotyping 612 
model (21). All 27 of the MGIT samples had high coverage, but several of the 613 
direct samples had low coverage (Figure 3a, bottom left). For this comparison we 614 
excluded pairs where the direct sample had <5x coverage to ensure like-with-615 
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like analysis, leaving 17 pairs. We then measured the number of SNP differences 616 
between the paired direct and MGIT samples, counting only sites where both 617 
genotypes had high confidence in our Illumina model (difference between log 618 
likelihood of called genotype (eg ALT allele) and of uncalled genotype (eg REF 619 
allele) greater than 1), and neither site was called as heterozygous. 620 
 621 
Samples were placed on the phylogenetic tree of 3480 samples from (1) by 622 
identifying the leaf with the fewest SNP differences, across the 68695 sites. 623 
Placement therefore returns a closest leaf, and a SNP distance to that leaf. 624 
 625 
Statistical analysis 626 
Univariable and multivariable linear regression was used to identify 627 
independent factors affecting log10 DNA concentration after extraction. Analyses 628 
were performed using Stata 14.1 (2015, StataCorp, USA). 629 
 630 
Bioinformatic Analysis of MinION Data 631 
Mykrobe predictor version v0.5.0-6-g6b19d83 was used to predict resistance 632 
from the MinION basecalled reads (command: mykrobe predict SAMPLE_ID tb -1 633 
FASTQ –panel walker-2015). This uses an ONT-specific genotyping model, a 634 
modification of that published in (21) – specifically it uses a Poisson model of 635 
total kmer counts on alternate alleles (instead of using the median kmer 636 
coverage), and applies a “genotype confidence” threshold of 100  (difference 637 
between log likelihood of called genotype (eg ALT allele) and of uncalled 638 
genotype (eg REF allele) greater than 100). Supplementary Figures 6,7 show the 639 
genotype confidence distribution split by whether the genotype is correct or not. 640 
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 641 
Yield and timing were analyzed using Poretools (23). For the R9.4 sample, 642 
Mykrobe predictor was applied to the cumulative read output at each hour. Yield 643 
of BCG was measured by mapping to a BCG reference (accession BX248333.1). 644 
 645 
Phylogenetic placement of the 15% spike BCG sample sequenced on MinION R9.4 646 
was achieved as for the Illumina data - by genotyping 68695 SNPs, and choosing 647 
the leaf with the fewest SNP differences across those sites. 648 
 649 
MinION error analysis  650 
Error bias in the consensus of MinION R9 1D pure BCG reads was measured in 651 
two ways, using reads from the pure BCG sequencing run described above. 652 
 653 
1. Reads were mapped to the M. tuberculosis reference genome using 654 
bwa_mem, and then this was passed to the consensus tool racon (24). The 655 
output of this was compared with the BCG reference genome using 656 
MUMMER (25). Since we were comparing M. bovis BCG strain with its own 657 
reference genome, any observed SNPs were either due to sequencing 658 
errors, or to evolution since the reference genome was constructed. We 659 
assumed the latter were negligible in comparison with the error rate in 660 
nanopore reads (Supplementary Figure 4), and considered all SNPs to be 661 
errors. Bias in these errors was observed by looking at isolated SNPs 662 
(avoiding alignment artefacts due to nearby indels). The results are 663 
shown in Supplementary Table 4. 664 
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2. A de novo assembly was performed with Canu (26), and then this was 665 
compared with the BCG reference genome using MUMMER, as above. 666 
Results are shown in Supplementary Table 5. 667 
 668 
The mapping approach ((1) above) found 28% of consensus errors were A->G 669 
and 60% were T->C. (Note these refer to the SNP with respect to the reference, 670 
not to errors within a single read passing through a pore.) The de novo assembly 671 
approach found 50% of consensus errors were A->G, and 44% were T->C. 672 
Although the estimates differed quantitatively, they agreed on the existence and 673 
direction of the bias. 674 
 675 
MinION turnaround estimates using empirical M. tuberculosis read 676 
proportion data 677 
 678 
The proportion of M. tuberculosis reads found in our clinical samples varied over 679 
a considerable range (Figure 2a, blue), with between 0.3% and 97.9% of 680 
sequenced DNA coming from M. tuberculosis. To model how this distribution 681 
might translate into MinION performance, we used hourly timestamps on the 682 
R9.4 MinION total DNA yield curve (Supplementary Figure 3), and coverage 683 
needed to detect M. tuberculosis, pyrazinamide resistance and full susceptibility 684 
results, to estimate the turnaround times for all Illumina-sequenced samples, 685 
supposing they all were to yield 1.3Gb of MinION reads with the same proportion 686 
of reads from M. tuberculosis as seen in Figure 2a. The results are displayed in 687 
Supplementary Figure 8 and Supplementary Table 6, with samples ordered by 688 
increasing proportion of M. tuberculosis.  689 
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 690 
Costing analysis 691 
Basic costing included reagents required for sample decontamination, DNA 692 
extraction, MiSeq and Nanopore library preparations, and sequencing; correct as 693 
of November 2016. Generic laboratory consumables (e.g. pipette tips, tubes) 694 
were not included. SureSelect (Agilent, UK) costs, as used by Brown et al. (18), 695 
were obtained via a company representative and were correct of June 2016. 696 
United States Dollars (USD) were converted to Great British Pounds (GBP) at 697 
$1.25 USD per GBP. See Supplementary Table 7 for details. 698 
 699 
Ethics 700 
For this study no ethical review was required because it was a laboratory 701 
methods development study focusing on bacterial DNA extracted from discarded 702 
samples identified only by laboratory numbers with no personal or clinical data. 703 
Sequencing reads identified as human based on fast mapping with BWA were 704 
counted and immediately permanently discarded (i.e. never stored 705 
electronically). 706 
 707 
Accession numbers  708 
The MiSeq, MiniSeq and MinION data have been deposited in the Sequence Read 709 
Archive (SRA), NCBI, under the study accession number SRP093599.  710 
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Table 1: Yield from pure BCG, and from negative sputum spiked with BCG – 906 
sequenced on Illumina MiniSeq  907 
 908 
 estimated 
Fmol 
loaded 
Yield (Mb) Read 
length (bp) 
BCG
reference 
coverage 
Pure BCG 
TB1_N716 
800 381 101 84.0
50 % BCG 
TB1_N718 
 
800 244 101 31.0
50% BCG 
TB1_N719 
800 257 101 33.0
 909 
 910 
Table 2: Yield from pure BCG, and from negative sputum spiked with BCG - 911 
both sequenced with MinION 1D protocol 912 
 913 
Model Sampl
e 
Fmol 
loaded 
Read 
count 
Yield/
Mb 
Avg 
read 
length 
(kb) 
BCG 
covg 
depth 
H57D 
R-
allele 
kmer 
covg+ 
% 
mutati
ons 
typed  
(# not 
typed) 
R9 Pure 
cultur
ed 
BCG 
++ 297,23
9 
360 1.2 80 17 99 (1)
R9 5% 
BCG 
LongA
mp 
82 182,67
0 
559 2.0 19 1* 47 
(93) 
R9 10% 
BCG 
LongA
mp 
76 180,50
7 
467 1.8 10 3 56 
(77) 
R9 15% 
BCG 
LongA
mp 
51 203,28
5 
627 2.0 35 3 90 
(18) 
R9 15% 27 184,89 758 2.4 68 10 98 (3)
 39
BCG 
Phusio
n 
5
R9.4 15% 
BCG 
Phusio
n 
43 754,33
8 
1306 1.7 147 16 100 
(0) 
 914 
+  kmer coverage on resistance allele of the H57D mutation in pncA, known to be 915 
present in BCG. 916 
++ data not available 917 
* resistance SNP detected but failed confidence threshold, and filtered out  918 
 919 
 920 
Table 3: Susceptibility prediction at timestamps during R9.4 run  921 
 922 
Hour %AMR  
mutations 
typed  
Number of 
mutations un-
genotyped 
(total 175) 
Un-genotyped 
mutations 
Drugs 
awaiting 
results 
1 57.1 75 * All except 
pyrazinamide 
2 88.5 20 katG (S700, 
L141, V633, 
W191, D142, 
L704) 
gid (L26, V41, 
G34, R47, 
G117, A205, 
R118, Q125) 
rpoB (H445) 
embB (D328, 
G406) 
rpsL (K43) 
pncA (T47, 
K48)** 
 
Isoniazid, 
streptomycin, 
rifampicin, 
ethambutol 
3 97.1 5 embB (D328)
gid (G34, 
A205) 
katG (W191) 
pncA (T47) 
Ethambutol, 
streptomycin, 
isoniazid  
4 98.2 3 gid (G34, 
A205) 
Streptomycin
 40
pncA (T47)
5 98.8 2 gid (G34)
pncA (T47) 
Streptomycin
 
6-9 99.4 1 pncA (T47)  - 
9 100 0 -  -  
 923 
* We omit list of un-genotyped mutations here; 75 is too many to list. 924 
** further un-genotyped pncA mutations could be ignored, as H57D had already 925 
been detected at 1 hour – sample already predicted to be pyrazinamide resistant. 926 
Thus pyrazinamide not listed in column 5. 927 
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Figure Legends 931 
 932 
 933 
Figure 1: DNA extracted (ng/ml) from MGIT cultures and direct clinical samples. 934 
Each dot represents a single extraction. Horizontal line at 0.2 ng/µl represents 935 
the DNA concentration theoretically required for MiSeq library preparation. 936 
Horizontal line at 0.05 ng/µl represents minimum DNA concentration used for 937 
MiSeq library preparation from direct samples in this study. One sample not 938 
shown as DNA was below detection limits. 939 
 940 
Figure 2: Proportion of reads assigned to various species categories in each 941 
sample sorted by increasing total count of MTBC reads. a) Direct samples show 942 
removal of human DNA (red) has been broadly successful, but removal of naso-943 
pharyngeal flora (NPF, green) and other bacteria (purple) had more variable 944 
success. b) MGIT samples show much more uniform dominance of M. 945 
tuberculosis reads, as expected after 2 weeks of culture designed to favor 946 
mycobacterial growth. 947 
 948 
Figure 3: Recovery of M. tuberculosis genome in direct samples and robustness 949 
to contamination. a) Depth versus proportion of the M. tuberculosis reference 950 
recovered (at >5x depth). Vertical dotted line at 3x depth is threshold used for 951 
resistance prediction in this study. b) Proportion of contamination (reads not 952 
mapping to M. tuberculosis reference) versus proportion of genome recovered. 953 
Samples with less than 95% of the M. tuberculosis genome recovered all have 954 
>75% contaminated reads. 955 
 42
 956 
Figure 4: Genotypic concordance between direct and paired MGIT samples.  a) 957 
Histogram of genetic (SNP) differences, excluding the one pair which differ by 958 
1106 SNPs; median (and modal) difference is 1 – thus direct sequencing is 959 
identifying the same strain of M. tuberculosis as culture-based sequencing would. 960 
b) Placing direct/MGIT pairs on a phylogenetic tree of 3480 samples shows 961 
distribution of samples across world diversity. Circle indicates the sequence 962 
from the direct sample and cross the sequence from the corresponding MGIT 963 
sample; for the 1 pair (of 17) with 1106 differences (turquoise), the MGIT sample 964 
places very close to other samples (0 SNP differences to one (MGIT) sample, 5 965 
SNP differences to others), and so is possibly due to a labeling error.  966 
 967 
 968 
Figure 5: Timelines and cost. We compare the method of Brown et al with the 969 
results of this study, using the Illumina MiSeq and MiniSeq, and the ONT MinION. 970 
We assume that no step of the process can be initiated after 6pm or before 8am. 971 
The method of Brown et al has a rapid extraction step, but also a 20 hour 972 
overnight enrichment step, resulting in a 50 hour turn-around time. The DNA 973 
extraction process was updated for the MiniSeq and MinION experiments, 974 
removing the ethanol precipitation step. In normal use this would take 3 hours. 975 
The 1.5 hour orange rectangle on the MinION timelines includes both PCR and 976 
the 10 minute sample preparation step. In this experiment, since we used spiked 977 
BCG DNA in sputum, we did not use a human depletion step, thus taking only 2 978 
hours. This figure is intended to show comparable real-use timelines, and so the 979 
MiniSeq/MinION timelines are shown with 3 hour extraction steps. The MiniSeq 980 
 43
enables a 16-hour turnaround time, by sequencing for only 7 hours. The R9 981 
MinION also delivers sub-24 hour results, but requires one flow-cell per sample. 982 
The R9.4 MinION gives a 12.5 hour turnaround time (6 hours of sequencing with 983 
real-time (i.e. simultaneous) basecalling when used on a single sample).  984 
 985 
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